Navigation Links
ProLindac in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... prolindac Showing High DACH Platinum Activity; Drug Well Tol...s in the Company's clinical development plan for prolindac , a novel DACH platinum drug that has shown t...lts from its Phase 2 monotherapy clinical study of prolindac (TM) in late-stage, heavily pretreated ovarian ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the v...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

... - prolindac Is Safe And Active in Recurrent Ovarian Cancer; Un... France where the level of anti-cancer activity of prolindac in a heavily-pretreated patient population compare...s in France, demonstrate the potential benefits of prolindac over current platinum therapies: one highlights th...
ProLindac in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... high dose groups achieved disease stabilization. prolindac was well tolerated overall. DALLAS, March 5 /...ffect of the approved DACH platinum, Eloxatin, and prolindac was well tolerated overall. The maximum tolerated dose of prolindac was established as well as the recommended dose le...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

...lop and commercialize Access' proprietary products prolindac and MuGard for the Republic of Korea. prolindac is Access' novel DACH platinum prodrug currently i...h a double digit royalty upon commercialization of prolindac and MuGard. In addition, in co-operation with Acce...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... prolindac Demonstrates Sustained and Significant Reductions ...Efficacy Results from an Ongoing Clinical Study of prolindac in Recurrent Ovarian Cancer." prolindac is Access' novel DACH platinum-polymer prodrug, wh...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...potential benefits for cancer therapy of combining prolindac with other anticancer agents. "These studies, whi...s year, provide further support to our belief that prolindac has the potential to become an important tool in t...he second poster demonstrates that combinations of prolindac with certain other anticancer compounds produces c...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...n San Francisco, CA. An update on Access' ongoing prolindac Phase 2 clinical study will be presented during Po...uesday, October 23, 2007 from 12:30 p.m. PDT. New prolindac preclinical data will appear in two posters presen...toxics, in human colon and ovarian cancer cells." prolindac is a novel DACH platinum prodrug which has been sh...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...titutes in France. "We are delighted to have two prolindac poster presentations at one of the most prestigiou...re platinum could be administered to patients with prolindac than oxaliplatin before the onset of toxicity. We are currently studying prolindac in a Phase 2 monotherapy trial, treating patients ...
ProLindac in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...nd that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue a...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... - Data demonstrates that prolindac should provide sustained tumor exposure to platinu...iopolymer" was presented on Monday, April 20. prolindac is Access' novel polymer-based DACH platinum prodr...ovides in vitro and ex-vivo data on the binding of prolindac to blood components, and suggests a mechanistic ra...

Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

...nd can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob . The replay can be obtained at the same link for 90 days. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals to Present at the Noble Financial Equity Conference

...ommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

...hese opportunities involve compounds that MacroChem believes show promising late-stage, pre-clinical and early clinical data. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...he Macau Special Administrative Region and Taiwan. prolindac is Access' novel DACH platinum prodrug currently i...r obtaining the necessary regulatory approvals for prolindac and commercializing the product in the Greater Chi...an of ASK. "We are excited about the potential for prolindac in China, and we are committed to bringing excitin...

Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

....wsw.com/webcast/rrshq13/accp.ob . The replay can be obtained at the same link for up to 90 days after the live presentation. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Announces $2.7 Million New Equity

... Stock will be amended. Closing of the transaction is subject to the fulfillment of customary and usual closing conditions. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...
Other Tags
(Date:11/24/2014)... 2014 The Healthy Skin Care Journal, ... affordable skin care products, recently announced its launch. Located ... a wide variety of articles, tips, and evaluations about ... skincare alternatives. , According to Emily Lataille, the website’s ... includes thoroughly researched reviews, tips for the skin, and ...
(Date:11/24/2014)... Alexandria, VA (PRWEB) November 24, 2014 ... will hold its 12th annual International Symposium on Malignant ... in Bethesda, Maryland. Daytime conference sessions will take place ... in Bethesda, while dinners, including a community dinner and ... Regency Bethesda. , Sessions will cover a range of ...
(Date:11/24/2014)... November 24, 2014 Abington Health ... MD has joined The Neurology Group and has ... Sclerosis Center. , A graduate of Vinnica Medical ... at Albert Einstein Medical Center in Philadelphia and completed ... Multiple Sclerosis Center at Weill Cornell Medical College. Ternopolska ...
(Date:11/24/2014)... A new sports massage technique available ... and massage therapy provider, announced it newest massage ... newest sports massage is a fast-acting, “to-the-point” ... sports massage and ESM is that ESM has ... "reset button,” and ESM can increase flexibility, elasticity, ...
(Date:11/24/2014)... November 24, 2014 Recently, SweetDressy.com, a ... unveiled its new collection of 2014 Evening Dresses. All ... According to the company’s marketing manager, the special offer ... for more. , Sweetdressy.com has been working well ... to unveil the latest designs. Their new dresses may ...
Breaking Medicine News(10 mins):Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
Other Contents